Curis reports updated emavusertib trial data in PCNSL... (Streetinsider.com) - Jul 22, 2026 - "In the PCNSL study, data as of July 1, 2026 showed that among evaluable BTKi-naïve patients, 5 of 5 achieved an objective response rate (ORR) of 100%, compared with 71% ORR reported in previous data from May 2025. Among BTKi-experienced evaluable patients, 10 of 30 achieved a 33% ORR, compared with 27% ORR previously reported across all patients."
P1/2 data • Primary Central Nervous System Lymphoma
|